| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
|
|
|
||||||
|
||||||||
Comparative Study |
Department of Hematology Oncology, University of Freiburg Hugstetterstr. 55, D-79106 Freiburg, Germany.
BACKGROUND AND OBJECTIVES. High-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are mainly diseases of patients over the age of 60 years. In these patients, intensive chemotherapy and/or allogeneic blood stem cell transplantation are the only curative treatment approaches, while non-curative options include low-dose chemotherapy or best supportive care alone. The basis for treatment decision-making in this clinically and biologically heterogeneous group is not well defined. DESIGN AND METHODS. In order to investigate treatment stratification patterns and outcomes in this population, we performed a systematic literature search in MedLine for relevant clinical reports published between 1989 and 2006. Only large population-based investigations and publications of clinical trials with more than 40 patients were analyzed. RESULTS. In 36 AML studies involving a total of 12,370 patients (median age 70 years) median overall survival approached 30 weeks for intensively treated patients. In patients receiving best supportive care alone, or best supportive care plus non-intensive treatment, median overall survival was 7.5 and 12 weeks, respectively. The complete remission rate after induction was 44%, and in those patients who achieved complete remission age no longer influenced prognosis. In 18 large studies approximately 50% of AML patients received induction therapy, 30% non-intensive chemotherapy and 20% supportive care only. INTERPRETATION AND CONCLUSIONS. Due to the scarcity of randomized AML/MDS trials in which older patients are assigned to either induction or less intense therapy, predictors to identify older patients most likely to benefit from intensive therapy and novel tools to optimize (or even standardize) recommendations are needed. We propose that in this patient population in the future, geriatric assessment instruments and comorbidity scoring are implemented in treatment decision-making.
This article has been cited by other articles:
|
|
 |
|
  D. Pulte, A. Gondos, and H. Brenner Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century Haematologica, April 1, 2008; 93(4): 594 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Sorror, S. Giralt, B. M. Sandmaier, M. De Lima, M. Shahjahan, D. G. Maloney, H. J. Deeg, F. R. Appelbaum, B. Storer, and R. Storb Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences Blood, December 15, 2007; 110(13): 4606 - 4613. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Sorror, B. M. Sandmaier, B. E. Storer, M. B. Maris, F. Baron, D. G. Maloney, B. L. Scott, H. J. Deeg, F. R. Appelbaum, and R. Storb Comorbidity and Disease Status Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation J. Clin. Oncol., September 20, 2007; 25(27): 4246 - 4254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Malcovati, U. Germing, A. Kuendgen, M. G. Della Porta, C. Pascutto, R. Invernizzi, A. Giagounidis, B. Hildebrandt, P. Bernasconi, S. Knipp, et al. Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes J. Clin. Oncol., August 10, 2007; 25(23): 3503 - 3510. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
